Indinol® [Indole carbinol]
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Indinol® Forto is a universal proofreader of pathological hyperplastic processes in breast tissue. The basis of the therapeutic effect of Indinol® Forto is its anti-estrogenic and anti-proliferative effect. The main property of Indinol® Forto is its ability to cause selective death of breast cells with abnormally high proliferative activity.
Indole carbinol, which is part of Indinol® Forto, modulates the cytochrome system in such a way that the resulting cytochrome P450 isoform — CYP1A1 hydroxylates the estrogens in the 2nd position, to form 2-hydroxyestrone (2-OH1). The resulting metabolite is an estrogen receptor antagonist and blocks its activation by the estrogens themselves, as well as their dangerous metabolites, in particular, 16-alpha-hydroxyestron (16α-ONE), the proportion of which among metabolites decreases. Thus, the induction of estrogen-dependent genes is suppressed, and the cell stops receiving excessive estrogen-dependent stimulation. The drug also blocks other signaling mechanisms (cytokine) that stimulate abnormal cell growth in breast tissue by suppressing signaling cascades from the corresponding receptors.
Course use of the drug helps to reduce the intensity and the disappearance of pain in the breast with cyclic mastalgia (mastodynia).
Use of the drug Indinol® Forto does not lead to an increase in body weight.
Indinol® Forto belongs to practically non-toxic drugs (LD50> 5 g / kg).
Cyclic mastalgia, including against the background of benign breast hyperplasia.
1 capsule contains:
Active substance: Indole carbinol (intrinol) - 0.200
Excipients: lactose monohydrate (milk sugar) - 0.140 g, modified corn starch - 0.095 g, microcrystalline cellulose - 0.064 g, magnesium stearate - 0.001 g
No customer reviews for the moment.
Dosage and Administration
Orally, 2 times a day, 200 mg. The daily dose of the drug is 400 mg. Capsules are taken before meals. Duration of treatment is 6 months.
From the reproductive system: menstrual disorders in the form of lengthening or shortening.
On the part of the digestive system: epigastric pain.
Laboratory indicators: increasing the concentration of thyrotropic and follicle-stimulating hormones, prolactin and estradiol, reducing the concentration of creatinine, eosinophilia.
Other: weight loss. If any of the side effects indicated in the instruction are aggravated, or you have noticed any other side effects that are not indicated in the instruction, inform your doctor.
The drug should not be used in the presence of any of the following conditions:
- hypersensitivity to the drug;
- hereditary intolerance to galactose, lactase deficiency or glucose-galactose malabsorption;
- the period of pregnancy and breastfeeding;
- children's age up to 18 years.
Indolkarbinol affect the activity of cytochrome P450 isoenzymes, so caution should be exercised when used together with drugs, metabolism involving isozymes of cytochrome P450 (oral anticoagulants, corticosteroids, oral hypoglycemic agents, antiarrhythmics, antiepileptics, digitalis preparations, preparations sex hormones) have been may require correction of their dose.
Pregnancy and Lactation
Use of the drug Indinol® Forto during pregnancy and breastfeeding is contraindicated.
Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention
Based on the characteristics of pharmacodynamics and the profile of undesirable effects, it is unlikely that Indinol® Forto has an impact on the ability to drive and work with technology.
Symptoms: Possible symptoms of an overdose include nausea, vomiting, diarrhea.
Treatment: specific antidote is unknown. If Indinol® Forto overdose is suspected, symptomatic therapy is recommended.
- Brand name: Indinol
- Active ingredient: Indole carbinol
- Dosage form: Capsules
- Manufacturer: MiraxBioFarma
- Country of Origin: Russia
- Chemopreventive properties of Indole-3-Carbinol (I3C): Inhibition of DNA adduct formation of the dietary carcinogen, 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b]Pyridine (PhIP), in female F344 rats
- Inhibition of DNA adduct formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3-methylimidazo[4,5-f]quinoline by dietary indole-3-carbinol in female rats
- Prior exposure to indole-3-carbinol decreases the incidence of specific cyclophosphamide-induced developmental defects in mice
- ChemInform Abstract: 1—1 The Chemistry and Pharmacology of Indole-3-carbinol (Indole-3-methanol) and 3-(Methoxymethyl)indole. Part 1.
- ChemInform Abstract: The Chemistry and Pharmacology of Indole-3-carbinol (Indole-3-methanol) and 3-(Methoxymethyl)indole. Part 2
- Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells
- Inhibition of MUC1 expression by indole-3-carbinol
- Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma
- Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells
- Indole-3-carbinol inhibits MDA-MB-231 breast cancer cell motility and induces stress fibers and focal adhesion formation by activation of Rho kinase activity
- Nucleophilic index value: Implication in the protection by indole-3-carbinol from N-nitrosodimethylamine cyto and genotoxicity in mouse liver
- Clinical development plan: Indole-3-carbinol
- The synthesis of [3H] - indole-3-carbinol, a natural anti-carcinogen from cruciferous vegetables
- Successful use of intralesional and intravenous cidofovir in association with indole-3-carbinol in an 8-year-old girl with pulmonary papillomatosis
- Metabolic fates of gramine in barley II: Biotransformation of gramine into indole-3-carbinol and indole-3-carboxylic acid in barley
- Broccoli-derived phytochemicals indole-3-carbinol and 3,3′-diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: Comparison with other cancer preventive phytochemicals
- A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands
- Targets for indole-3-carbinol in cancer prevention
- Estrogen receptor α as a target for indole-3-carbinol
- Indole-3-carbinol enhances oxidative stress responses resulting in the induction of preneoplastic liver cell lesions in partially hepatectomized rats initiated with diethylnitrosamine
- Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma
- The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line
- Inhibition of proliferation of a colon cancer cell line by indole-3-carbinol